Adverse Event Reporting

VAERS ID	1390236
Gender	Female
Age
StateCode	FR
Pharmaceutical Company	PFIZER\BIONTECH
Lot Number	EY2173
Number of vaccinations	1
Vaccinated
Onset
Condition

Symptoms

• Anaphylactic shock

Current Illness

Preexisting Conditions

Other Medications

Previous Vaccinations

Allergies

Laboratory Data

Write-up

Anaphylactic shock; This is a spontaneous report received from a contactable pharmacist.
A female patient in her 20s received bnt162b2 (COMIRNATY, solution for injection, lot number EY2173, expiration date 31Aug2021), on unspecified date as 1st dose, single dose for COVID-19 immunisation.
The patient's medical history and concomitant medications were not reported.
On unspecified time/date the patient experienced anaphylactic shock.
As per details it was reported that a staff had anaphylactic shock after the first vaccination.
The outcome of the event was not provided.
; Sender's Comments: Based on chronological connection to the vaccine and known product safety profile, causality between event anaphylactic shock and BNT162B2 ((COMIRNATY) vaccine cannot be excluded.
.
The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events.
Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to Regulatory Authorities, Ethics Committees and Investigators, as appropriate.